Is bismuth quadruple therapy effective for treating H. pylori in Peptic Ulcer cases?

Bismuth quadruple therapy (BQT) is a combination of four medicines: a proton pump inhibitor (a drug that cuts stomach acid), bismuth (a compound that coats and protects the stomach lining), and two antibiotics. It is one of the main recommended treatments for Helicobacter pylori (H. pylori), the bacterium that causes most peptic ulcers. The short answer is yes: BQT is effective and is a preferred first-line option, especially in places where clarithromycin resistance is common ⁷¹⁰.

What the research says

A 2022 Chinese national clinical practice guideline on H. pylori eradication confirms that H. pylori causes peptic ulcer and that eradication treatment can control disease progression and lower the risk of complications ¹¹. That guideline and a 2023 review both note that rising antibiotic resistance is making eradication harder, which is why bismuth-based regimens have become more important ⁷¹¹. A 2023 narrative review reports that current recommendations for first-line treatment in areas with high clarithromycin resistance include bismuth quadruple and concomitant regimens, which achieve eradication rates above 85% ⁷. A 2023 American Family Physician review similarly states that bismuth quadruple therapy or concomitant therapy is the preferred first-line treatment for H. pylori eradication because of increasing clarithromycin resistance ¹⁰.

What to ask your doctor

• Is bismuth quadruple therapy the right first-line choice for my H. pylori infection, given local resistance patterns?
• How will we confirm that the infection is gone after treatment (for example, a urea breath test or stool antigen test)?
• What side effects should I expect from bismuth quadruple therapy, and how should I manage them?
• If I have already tried one course of treatment, what are the options for a second attempt?
• Do I need to avoid NSAIDs or take a proton pump inhibitor long term to protect against another ulcer?